Literature DB >> 16855786

The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.

Michael Zeidler1, Celina G Kleer.   

Abstract

The Polycomb group protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to tumorigenesis in multiple organs. In this review we summarize the current knowledge on the function of EZH2 in cancer, with special focus on breast cancer, and propose a link between EZH2, the homologous recombination pathway of DNA repair, and breast tumorigenesis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16855786     DOI： 10.1007/s10735-006-9042-9

Source DB:  PubMed          Journal:  J Mol Histol        ISSN： 1567-2379            Impact factor:   2.611


  31 in total

1.  The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.

Authors:  H P Visser; M J Gunster; H C Kluin-Nelemans; E M Manders; F M Raaphorst; C J Meijer; R Willemze; A P Otte
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

2.  Nucleotide sequence of bup, an upstream gene in the bmi-1 proviral insertion locus.

Authors:  Y Haupt; G Barri; J M Adams
Journal:  Mol Biol Rep       Date:  1992-11       Impact factor: 2.316

Review 3.  Division of labor in polycomb group repression.

Authors:  Stuart S Levine; Ian F G King; Robert E Kingston
Journal:  Trends Biochem Sci       Date:  2004-09       Impact factor: 13.807

4.  Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice.

Authors:  Y Haupt; W S Alexander; G Barri; S P Klinken; J M Adams
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

5.  Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

Authors:  Serdar Arisan; Elif Damla Buyuktuncer; Narcin Palavan-Unsal; Turhan Caşkurlu; Omer Onur Cakir; Erbil Ergenekon
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

6.  Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation.

Authors:  J van der Vlag; A P Otte
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

7.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

Authors:  Ingeborg M Bachmann; Ole J Halvorsen; Karin Collett; Ingunn M Stefansson; Oddbjørn Straume; Svein A Haukaas; Helga B Salvesen; Arie P Otte; Lars A Akslen
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

8.  The murine polycomb-group genes Ezh1 and Ezh2 map close to Hox gene clusters on mouse chromosomes 11 and 6.

Authors:  G Laible; A R Haynes; A Lebersorger; D O'Carroll; M G Mattei; P Denny; S D Brown; T Jenuwein
Journal:  Mamm Genome       Date:  1999-03       Impact factor: 2.957

9.  The Polycomb group protein EZH2 directly controls DNA methylation.

Authors:  Emmanuelle Viré; Carmen Brenner; Rachel Deplus; Loïc Blanchon; Mario Fraga; Céline Didelot; Lluis Morey; Aleyde Van Eynde; David Bernard; Jean-Marie Vanderwinden; Mathieu Bollen; Manel Esteller; Luciano Di Croce; Yvan de Launoit; François Fuks
Journal:  Nature       Date:  2005-12-14       Impact factor: 49.962

10.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702
View more
  9 in total

Review 1.  Polycomb and the emerging epigenetics of pancreatic cancer.

Authors:  Adrienne Grzenda; Tamas Ordog; Raul Urrutia
Journal:  J Gastrointest Cancer       Date:  2011-06

Review 2.  Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2015-07-30       Impact factor: 12.944

3.  A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2.

Authors:  Yan Wang; Jingyi Ma; Sheung Ching Chow; Chi Han Li; Zhangang Xiao; Ru Feng; Jie Fu; Yangchao Chen
Journal:  Tumour Biol       Date:  2013-07-30

4.  Identification of Polycomb Group Protein EZH2-Mediated DNA Mismatch Repair Gene MSH2 in Human Uterine Fibroids.

Authors:  Qiwei Yang; Archana Laknaur; Lelyand Elam; Nahed Ismail; Larisa Gavrilova-Jordan; John Lue; Michael P Diamond; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2016-03-31       Impact factor: 3.060

5.  Ezh2, a novel target in detection and therapy of breast cancer.

Authors:  Sarah Pourakbar; Timothy J Pluard; Anthony D Accurso; Faris Farassati
Journal:  Onco Targets Ther       Date:  2017-05-22       Impact factor: 4.147

6.  Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma.

Authors:  Karen M Chisholm; Yue Wan; Rui Li; Kelli D Montgomery; Howard Y Chang; Robert B West
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

7.  Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression.

Authors:  Adrienne Grzenda; Gwen Lomberk; Phyllis Svingen; Angela Mathison; Ezequiel Calvo; Juan Iovanna; Yuning Xiong; William Faubion; Raul Urrutia
Journal:  Epigenetics Chromatin       Date:  2013-02-28       Impact factor: 4.954

8.  A polycomb group protein, PHF1, is involved in the response to DNA double-strand breaks in human cell.

Authors:  Zehui Hong; Jie Jiang; Li Lan; Satoshi Nakajima; Shin-ichiro Kanno; Haruhiko Koseki; Akira Yasui
Journal:  Nucleic Acids Res       Date:  2008-04-01       Impact factor: 16.971

9.  The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter.

Authors:  Lu Gan; Midie Xu; Ruixi Hua; Cong Tan; Jieyun Zhang; Yiwei Gong; Zhenhua Wu; Weiwei Weng; Weiqi Sheng; Weijian Guo
Journal:  J Hematol Oncol       Date:  2018-01-15       Impact factor: 17.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.